Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ENVISION HEALTHCARE OPERATING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Federal regulatory and legislative matters affecting Medicare physician payment, including the Medicare Physician Fee Schedule, the No Surprises Act/IDR process, and related Medicaid provisions.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Source: Senate LDA
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Medicare physician fee schedule issues.
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Independent dispute resolution under the No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVISION HEALTHCARE OPERATING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
Federal regulatory and legislative matters affecting Medicare physician payment, including the Medicare Physician Fee Schedule, the No Surprises Act/IDR process, and related Medicaid provisions.
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
Independent dispute resolution under the No Surprises Act.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare physician fee schedule issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Medicare physician fee schedule issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · third_quarter · Q3
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · second_quarter · Q2
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · first_quarter · Q1
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Medicare reimbursement, including the Medicare Physician Fee Schedule. Healthcare consolidation, including the Health Over Wealth Act (draft legislation).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2024 · second_quarter · Q2
Medicare reimbursement, including the Medicare Physician Fee Schedule. Healthcare consolidation, including the Health Over Wealth Act (draft legislation).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2024 · first_quarter · Q1
Medicare reimbursement.
Filing targets: SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2023 · fourth_quarter · Q4
Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2023 · third_quarter · Q3
Corporatization and Consolidation in Health Care; Private Equity, Medicare Reimbursement; Dermatology Research Issues.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2023 · third_quarter · RR
Corporatization and Consolidation in Health Care; Private Equity, Medicare Reimbursement; Dermatology Research Issues.